Form 4: Director Julie Smith Receives RSU Grant at Exelixis

Exelixis, Inc. director Julie Smith was granted 8,367 restricted stock units as part of the company's 2017 Equity Incentive Plan.

Summary

• Director Julie Smith acquired 8,367 restricted stock units (RSUs) on May 27, 2026.
• The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU represents the economic equivalent of one share of common stock.
• The total beneficial ownership for the director following this transaction is 28,957 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant market-moving implications.

Positives

• The grant aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting of the RSUs is subject to the director's continuous service through the May 27, 2027, vesting date.

Future Outlook

The RSUs are scheduled to vest 100% on May 27, 2027, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholder interests.

Comparison to Industry Standards

• The use of RSU grants for director compensation is consistent with standard practices for mid-to-large cap biotechnology firms like Exelixis.
• Vesting schedules of one year for director equity are common in the industry to maintain board stability.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 8,367 RSUs on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation